Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
iBio Announces New Investments from Board Members and Officers
-
Braves Announce Exclusive Gray Media Spring Training Action
-
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
-
Oatly to Report Fourth Quarter 2024 Financial Results on February 12, 2025
-
Mastercard and FreedomPay Unlock Global Commerce With New Payment Gateway Partnership
-
Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer
-
EDAP Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures
-
ClearView Healthcare Partners Makes Strategic Investment in Epistemic AI to Advance Next-Generation Biomedical AI Platform
-
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America
-
Schouw & Co. share buy-back programme, week 2 2025
-
Avacta Appoints Brian Hahn as Chief Financial Officer
-
Devon Energy Announces Updates to Executive Leadership Team
-
Alamos Gold Continues to Define High-Grade Mineralization Across the Island Gold Deposit; Ongoing Success Expected to Drive Additional Growth in Mineral Reserves and Resources
-
Pharvaris Outlines 2025 Strategic Priorities
-
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook
-
Goliath Drills Remarkable Hole Assaying 34.52 g/t AuEq (1.11 oz/T AuEq) Over 39.00 Meters, Including 132.93 g/t AuEq (4.27 oz/T AuEq) Over 10.00 Meters, Plus Several High-Grade Holes With Multiple Int
-
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
-
Brazil Potash Subsidiary Potássio do Brasil, Signs Preliminary Agreement with Mura Indigenous People for Autazes Potash Project
-
Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2024 and Provides Initial 2025 Revenue Guidance
-
AirSculpt Technologies Updates Fiscal Year 2024 Guidance in Advance of its Participation in the ICR Conference 2025
-
Fincover®.com Launches Revolutionary Fintech Marketplace for Financial Services
-
Nomad Internet Announced the Unlimited Power Plan, Offering High-Speed Internet, Unlimited Data, and a Free Modem
-
Form 8.5 (EPT/RI) - Brand Architekts Group plc
-
PACS FINAL DEADLINE ALERT: PACS Group (PACS) Investors Alerted to Today’s Lead Plaintiff Deadline in Securities Class Action
-
Dimensional Fund Advisors Ltd. : Form 8.3 - INTERNATIONAL PAPER CO - Ordinary Shares
-
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
-
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
-
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
-
Comstock Releases Shareholder Letter
-
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
-
First Atlantic Nickel Closes Acquisition of RPM South Claims at the Atlantic Nickel Project
-
Westport Announces Director Retirement
-
Nova Minerals Identifies Stibium Gold-Antimony Resource Drill Targets on its Estelle Gold and Critical Minerals Project, in Alaska
-
Dimensional Fund Advisors Ltd. : Form 8.3 - HARGREAVES LANSDOWN PLC - Ordinary Shares
-
Auction result of Treasury Bills - RIKV 25 0416 - RIKV 25 0820
-
Form 8.5 (EPT/RI) - Warpaint London Plc
-
Dimensional Fund Advisors Ltd. : Form 8.3 - BRITVIC PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - ALLIANCE PHARMA PLC - Ordinary Shares
-
Labviva Secures $25M to Accelerate Product Development and Global Expansion
-
Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
-
Invitation to HMS Networks’ fourth quarter conference call 2024
-
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
-
HSBC Bank Plc - Form 8.5 (EPT/RI) - Team Internet Group plc
-
First Quantum Provides Notice of Fourth Quarter and Year-End 2024 Results
-
Niels Erik Jakobsen, Managing Director, retires
-
NewGen Launches Innovative Lifetime Egg Freezing Service to Address Growing Market Need in Asia
-
Armada Hoffler Completes Full-Floor Office Lease at Town Center of Virginia Beach
-
R3 Vascular Secures WCG IRB Approval and CMS Category B Medicare Coverage for the ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peri
-
Crown Reminds Shareholders to Vote Ahead of Special Meeting on January 14th
-
Leading US health systems launch the Truveta Genome Project, creating the world’s largest and most diverse database to discover the science of humanity
